secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2024-01-29T23:59:59+00:00
Accession:  0001193125-24-018071
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics no salary increase for 2024; option grants to officers
--------------------------------------------------------------------------

- No salary increase for executive officers in 2024; Committee approved stock option grants.
- CEO Dirk Thye: $302,500 bonus, 1,500,000 options vesting monthly over 4 years.
- President Charles Ryan: $70,000 bonus, 145,000 options; COO Brendan Hannah: $178,500 bonus, 600,000 options.
- Option grants effective Feb 1, 2024 under 2019 Equity Incentive Plan; vesting over 4 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312524018071/0001193125-24-018071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312524018071/d661573d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-018071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer